Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 02/20/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CALT vs. KRYS, SWTX, BHVN, RXRX, PTCT, OGN, RARE, ALVO, RNA, and ADMAShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), Biohaven (BHVN), Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Avidity Biosciences (RNA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Krystal Biotech SpringWorks Therapeutics Biohaven Recursion Pharmaceuticals PTC Therapeutics Organon & Co. Ultragenyx Pharmaceutical Alvotech Avidity Biosciences ADMA Biologics Krystal Biotech (NASDAQ:KRYS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment. Do analysts recommend KRYS or CALT? Krystal Biotech currently has a consensus target price of $210.00, indicating a potential upside of 11.79%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, indicating a potential downside of 1.88%. Given Krystal Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Krystal Biotech is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in KRYS or CALT? 86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 14.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, KRYS or CALT? Krystal Biotech has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Does the media favor KRYS or CALT? In the previous week, Krystal Biotech had 32 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 32 mentions for Krystal Biotech and 0 mentions for Calliditas Therapeutics AB (publ). Krystal Biotech's average media sentiment score of 0.75 beat Calliditas Therapeutics AB (publ)'s score of -0.31 indicating that Krystal Biotech is being referred to more favorably in the media. Company Overall Sentiment Krystal Biotech Positive Calliditas Therapeutics AB (publ) Neutral Is KRYS or CALT more profitable? Krystal Biotech has a net margin of 30.69% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Krystal Biotech's return on equity of 11.41% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech30.69% 11.41% 10.40% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has better earnings and valuation, KRYS or CALT? Krystal Biotech has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$290.52M18.60$10.93M$2.9962.83Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the MarketBeat Community favor KRYS or CALT? Krystal Biotech received 266 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 67.51% of users gave Krystal Biotech an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformKrystal BiotechOutperform Votes29367.51% Underperform Votes14132.49% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% SummaryKrystal Biotech beats Calliditas Therapeutics AB (publ) on 17 of the 19 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-21.626.1326.4618.82Price / Sales0.74313.78457.6880.73Price / CashN/A67.8344.0437.47Price / Book37.746.747.634.64Net Income-$43.96M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.02%-1.82%-2.63%1 Month PerformanceN/A-1.54%0.22%-2.37%1 Year Performance97.04%-3.14%17.49%13.65% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)0.1154 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180KRYSKrystal Biotech4.4767 of 5 stars$153.24-1.6%$206.67+34.9%+63.6%$4.41B$50.70M86.58210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSWTXSpringWorks Therapeutics1.2527 of 5 stars$57.43-2.0%$70.83+23.3%+22.8%$4.27B$5.45M-14.80230Earnings ReportAnalyst ForecastInsider TradeNews CoverageBHVNBiohaven3.3776 of 5 stars$41.45-0.8%$63.15+52.4%-15.8%$4.19BN/A-4.43239Short Interest ↓RXRXRecursion Pharmaceuticals1.5231 of 5 stars$10.53+23.9%$8.75-16.9%-17.8%$4.11B$64.60M-6.88400High Trading VolumePTCTPTC Therapeutics3.6197 of 5 stars$51.82+4.3%$58.85+13.6%+93.9%$4.00B$937.82M-8.721,410Analyst ForecastNews CoverageOGNOrganon & Co.4.8637 of 5 stars$15.30-6.3%$20.80+36.0%-15.2%$3.94B$6.26B3.0310,000RAREUltragenyx Pharmaceutical4.6097 of 5 stars$42.49-2.4%$92.43+117.5%-7.1%$3.92B$434.25M-6.571,276Analyst ForecastALVOAlvotech2.6284 of 5 stars$12.99+1.6%$18.00+38.6%-26.7%$3.92B$391.87M-7.021,026News CoverageRNAAvidity Biosciences1.613 of 5 stars$32.31-2.2%$65.80+103.7%+132.7%$3.85B$9.56M-11.22190ADMAADMA Biologics3.5404 of 5 stars$15.90-1.1%$21.25+33.6%+212.2%$3.76B$258.21M56.79530 Related Companies and Tools Related Companies Krystal Biotech Alternatives SpringWorks Therapeutics Alternatives Biohaven Alternatives Recursion Pharmaceuticals Alternatives PTC Therapeutics Alternatives Organon & Co. Alternatives Ultragenyx Pharmaceutical Alternatives Alvotech Alternatives Avidity Biosciences Alternatives ADMA Biologics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
